Authors:
Latif, F
Tandon, S
Obeleniene, R
Hankins, SR
Berlowitz, MS
Ennezat, PV
Le Jemtel, TH
Citation: F. Latif et al., Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects, J CARD FAIL, 7(3), 2001, pp. 265-268
Authors:
Ennezat, PV
Malendowicz, SL
Testa, M
Colombo, PC
Cohen-Solal, A
Evans, T
LeJemtel, TH
Citation: Pv. Ennezat et al., Physical training in patients with chronic heart failure enhances the expression of genes encoding antioxidative enzymes, J AM COL C, 38(1), 2001, pp. 194-198
Authors:
Berlowitz, MS
Latif, F
Hankins, SR
Ennezat, PV
Moskowitz, R
Tandon, S
Colombo, PC
Le Jemtel, TH
Citation: Ms. Berlowitz et al., Dose-dependent blockade of the angiotensin II type 1 receptor with losartan in normal volunteers, J CARDIO PH, 37(6), 2001, pp. 692-696
Authors:
Tabet, JY
Logeart, D
Geyer, C
Guiti, C
Ennezat, PV
Dahan, M
Cohen-Solal, A
Citation: Jy. Tabet et al., Comparison of the prognostic value of left ventricular filling and peak oxygen uptake in patients with systolic heart failure, EUR HEART J, 21(22), 2000, pp. 1864-1871
Authors:
Baillard, C
Mansier, P
Ennezat, PV
Mangin, L
Medigue, C
Swynghedauw, B
Chevalier, B
Citation: C. Baillard et al., Converting enzyme inhibition normalizes QT interval in spontaneously hypertensive rats, HYPERTENSIO, 36(3), 2000, pp. 350-354
Authors:
Malendowicz, SL
Ennezat, PV
Testa, M
Murray, L
Sonnenblick, EH
Evans, T
LeJemtel, TH
Citation: Sl. Malendowicz et al., Angiotensin II receptor subtypes in the skeletal muscle vasculature of patients with severe congestive heart failure, CIRCULATION, 102(18), 2000, pp. 2210-2213
Authors:
Jorde, UP
Ennezat, PV
Lisker, J
Suryadevara, V
Infeld, J
Cukon, S
Hammer, A
Sonnenblick, EH
Le Jemtel, TH
Citation: Up. Jorde et al., Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure, CIRCULATION, 101(8), 2000, pp. 844-846